Key result
Atherosclerosis and diabetes linked to lower intraplatelet PF4 and greater plasma PF4 release following IV heparin.
Why the study?
Does the intraplatelet level of PF4 and the heparin-mobilisable pool of PF4 differ between patients with atherosclerosis or diabetes and healthy controls?
Population
Patients with clinical evidence of atherosclerosis and patients with diabetes, along with appropriate…
Comparison
Intravenous heparin injection. vs Appropriate controls without atherosclerosis or…
Design
Cross-sectional
Follow-up
24 hours
Authors
Loading...
May affect heparin responses in atherosclerosis and diabetes; leaves open clinical relevance for dosing or events.
Case-Control
Does the intraplatelet level of PF4 and the heparin-mobilisable pool of PF4 differ between patients with atherosclerosis or diabetes and healthy controls?
Patients with atherosclerosis and diabetes have altered platelet PF4 content and an exaggerated release of PF4 in response to heparin compared to controls.
O’Brien et al. (1984) conducted a case-control in Atherosclerosis and diabetes. Atherosclerosis and diabetes vs. Controls was evaluated on Intraplatelet level of platelet factor 4 (PF4) and heparin-mobilisable pool of PF4. Patients with atherosclerosis and diabetes had significantly decreased intraplatelet PF4 levels and liberated more PF4 into plasma following intravenous heparin compared to controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: